Akari Therapeutics, Plc Share Price & Technical Analysis
AKTX · $17.81 (-2.52%)
Healthcare / Biotechnology
$17.81
-2.52%
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat so…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
218% return in May, 0% avg return in past 3 year May month.
156% return in 2026, -84% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -19% | -4% | -43% | 4% | 218% | – | – | – | – | – | – | – | 156% |
| 25 | -11% | -21% | 46% | 13% | -6% | -13% | -13% | -26% | 31% | -24% | -36% | -40% | -101% |
| 24 | -15% | -10% | -20% | -17% | 11% | 50% | 36% | 1% | -21% | -14% | -52% | -2% | -53% |
| 23 | 5% | -30% | -49% | -9% | -7% | -9% | 47% | -37% | 14% | -15% | -14% | 6% | -97% |
| 22 | -7% | -1% | -8% | 1% | 6% | -12% | 14% | 2% | -46% | -25% | 16% | -15% | -74% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Overbought
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.49M
P/E ratio
—
52W high
$56.80
52W low
$3.02
Volume
24,92,849
Beta
0.65
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Akari Therapeutics, Plc share price today?
- Akari Therapeutics, Plc (AKTX) last traded around $17.81 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AKTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AKTX. Download the app for real-time alerts.
- How can I analyze Akari Therapeutics, Plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.